Surveillance for adverse events following immunization (AEFI) in Switzerland-1991-2001

Vaccine

Volumn 28, Issue 24, 2010, Pages 4059-4064

  Schumacher, Z ^a   Bourquin, C ^b   Heininger, U ^a  

^a UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

^b FEDERAL OFFICE OF PUBLIC HEALTH   (Switzerland)

Author keywords

AEFI (adverse events following immunization); Passive; Surveillance

Indexed keywords

BCG VACCINE; DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HEPATITIS A HEPATITIS B VACCINE; HEPATITIS A VACCINE; HEPATITIS B VACCINE; INFLUENZA VACCINE; MEASLES MUMPS RUBELLA VACCINE; ORAL POLIOMYELITIS VACCINE; POLIOMYELITIS VACCINE; TICK BORNE ENCEPHALITIS VACCINE; TYPHOID VACCINE; UNCLASSIFIED DRUG; VACCINE; YELLOW FEVER VACCINE;

AGE DISTRIBUTION; ANAPHYLAXIS; ARTICLE; DISEASE SEVERITY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; HUMAN; IMMUNIZATION; INCIDENCE; INJECTION SITE SWELLING; LIMB SWELLING; NEUROLOGIC DISEASE; PRIORITY JOURNAL; SWITZERLAND; SYSTEMIC DISEASE; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ADVERSE DRUG REACTION REPORTING SYSTEMS; AGE DISTRIBUTION; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; IMMUNIZATION; INFANT; MALE; SWITZERLAND;

EID: 77952584728     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.04.002     Document Type: Article

References (24)

1. Bonhoeffer J., Kohl K., Chen R., Duclos P., Heijbel H., Heininger U., et al. The Brighton Collaboration-enhancing vaccine safety. Vaccine 22 4 (2004) 2046
2. Bonhoeffer J., and Heininger U. Adverse events following immunization: perception and evidence. Curr Opin Infect Dis 20 3 (2007) 237-246
3. Schweizerisches Heilmittelgesetz (HMG, Artikel 59), Schweizerische Arzneimittelverordnung (VAM, Artikel 35-39).
4. Bundesamt für Gesundheit. Impfkomplikationen - Meldungen von zeitlich mit Impfungen assoziierten Symptomen. BAG Bull 13 (1993) 236-243
5. http://www.who.int/vaccines-documents/DocsPDF05/815.pdf
6. Fisher L.D., and van Belle G. Biostatistics-a methodology for the health sciences. Wiley series in probability and mathematical statistics (1993), John Wiley & Sons, Inc., New York
7. Jonville-Béra A.P., Autret-Leca E., Barbeillon F., and Paris-Llado J. French Reference Centers for SIDS. Sudden unexpected death in infants under 3 months of age and vaccination status-a case-control study. Br J Clin Pharmacol 51 3 (2001) 271-276
8. Fleming P.J., Blair P.S., Platt M.W., Tripp J., Smith I.J., and Golding J. The UK accelerated immunisation programme and sudden unexpected death in infancy: case-control study. BMJ 322 7290 (2001) 822-825
9. Khromava A.Y., Eidex R.B., Weld L.H., Kohl K.S., Bradshaw R.D., Chen R.T., et al. Yellow fever vaccine: an updated assessment of advanced age as a risk factor for serious adverse events. Vaccine 23 25 (2005) 3256-3263
10. Ritter O., Bonz A., Strotmann J., and Langenfeld H. Myocardial infarction after influenza vaccination. Z Kardiol 92 11 (2003) 962-965
11. Singleton J.A., Lloyd J.C., Mootrey G.T., Salive M.E., Chen R.T., and VAERS Working Group. An overview of the vaccine adverse event reporting system (VAERS) as a surveillance system. Vaccine 17 22 (1999) 2908-2917
12. Varricchio F., Iskander J., Destefano F., Ball R., Pless R., Braun M.M., et al. Understanding vaccine safety information from the Vaccine Adverse Event Reporting System. Pediatr Infect Dis J 23 4 (2004) 287-294
13. Keller-Stanislawski B., Heuss N., and Meyer C. Adverse events following immunisation in Germany from 1.1.2001 to 31.12.2003. Bundesgesundheitsbl - Gesundheitsforsch - Gesundheitsschutz 47 12 (2004) 1151-1164
14. Lawrence G., Boyd I., McIntyre P., and Isaacs D. Annual report: surveillance of adverse events following immunisation in Australia, 2005. Commun Dis Intell 30 3 (2006) 319-333
15. Braun M.M., and Ellenberg S.S. Descriptive epidemiology of adverse events after immunization: reports to the Vaccine Adverse Event Reporting System (VAERS), 1991-1994. J Pediatr 131 4 (1997) 529-535
16. Heininger U., The DTP-HBV-IPV-059 and -096 Study Group, Sänger R., Jacquet J.M., and Schuerman L. Booster immunization with a hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus vaccine and Haemophilus influenzae type b conjugate combination vaccine in the second year of life: Safety, immunogenicity and persistence of antibody responses. Vaccine 25 6 (2007) 1055-1063
17. Wakefield A.J., Murch S.H., Anthony A., Linnell J., Casson D.M., Malik M., et al. Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children. Lancet 351 9103 (1998) 637-641
18. Schattner A. Consequence or coincidence? The occurrence, pathogenesis and significance of autoimmune manifestations after viral vaccines. Vaccine 23 30 (2005) 3876-3886
19. Miller E. Measles-mumps-rubella vaccine and the development of autism. Semin Pediatr Infect Dis 14 3 (2003) 199-206
20. Hernan M.A. Recombinant hepatitis B vaccine and the risk of multiple sclerosis-a prospective study. Neurology 63 5 (2004) 838-842
21. Ascherio A., Zhang S.M., Hernán M.A., Olek M.J., Coplan P.M., Brodovicz K., et al. Hepatitis B vaccination and the risk of multiple sclerosis. N Engl J Med 344 5 (2001) 327-332
22. Monteyne P., and André F.E. Is there a causal link between hepatitis B vaccination and multiple sclerosis?. Vaccine 18 19 (2000) 1994-2001
23. Rosenthal S., and Chen R. The reporting sensitivities of two passive surveillance systems of vaccine adverse events. Am J Public Health 85 12 (1995) 1706-1709
24. Scheifele D.W., and Halperin S.A. CPS/Health Canada, Immunization Monitoring Program, Active (IMPACT). Immunization Monitoring Program, Active: a model of active surveillance of vaccine safety. Semin Pediatr Infect Dis 14 3 (2003) 213-219